Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIDIL vs FINGOLIMOD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Off-label: chronic inflammatory demyelinating polyneuropathy (CIDP)
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
0.5 mg orally once daily
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Primarily metabolized by CYP4F2 via ω-hydroxylation; minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Also undergoes reversible phosphorylation to active metabolite fingolimod-phosphate.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Approximately 90% bound to plasma proteins, primarily albumin.
>99.7% bound to human serum albumin; minor binding to lipoproteins.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Vd approximately 1000 L/kg (17,000 L); extensive distribution into tissues, particularly lung, blood cells, and CNS.
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
Oral bioavailability is approximately 93% following a single 5 mg dose; food does not significantly affect absorption.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Contraindicated.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
For patients 10 years and older weighing >40 kg: 0.5 mg orally once daily. For patients <10 years or ≤40 kg: Not recommended.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
No specific dose adjustment; monitor for bradycardia and atrioventricular block due to age-related conduction system changes. Caution in patients ≥65 years due to limited data.
None
Risk of serious infections; cases of fatal herpes infections (e.g., varicella zoster) reported. Requires baseline VZV serology and vaccination if negative.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Bradyarrhythmia and AV block (monitor for 6 hours after first dose), increased infection risk (especially herpes viruses), macular edema (ophthalmologic exam at baseline and 3-4 months after initiation), progressive multifocal leukoencephalopathy (PML), posterior reversible encephalopathy syndrome (PRES), severe exacerbation of MS after discontinuation, respiratory effects (decline in FEV1 and DLCO), liver injury, fetal risk, blood pressure effects (hypertension), and risk of basal cell carcinoma.
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Patients with recent myocardial infarction (within 6 months), unstable angina, stroke, transient ischemic attack, decompensated heart failure, or history of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome (unless pacemaker in place), severe active infections, and hypersensitivity to fingolimod or any of its excipients.
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
Grapefruit juice and Seville oranges may increase drug levels; avoid consumption.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular septal defects, particularly during the first trimester. Human data are limited, but case reports suggest potential fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
Fingolimod is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 2:1. Based on a typical maternal dose, the estimated infant exposure is about 0.2-0.4% of the maternal weight-adjusted dose. Due to potential for serious adverse effects (immunosuppression, bradycardia), breastfeeding is not recommended during fingolimod therapy.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
No specific dose adjustment guidelines exist for fingolimod during pregnancy due to teratogenicity. Pregnancy is a contraindication; discontinue fingolimod before conception or as soon as pregnancy is detected. Pharmacokinetic studies in pregnancy are lacking; no evidence of altered metabolism requiring dose adjustment if used inadvertently.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
First-dose monitoring required for 6 hours due to bradycardia risk; obtain baseline ECG, CBC, LFTs. Avoid live vaccines; screen for latent infections. Rebound disease activity may occur upon discontinuation; taper not needed but monitor closely.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
Your heart rate will be monitored for 6 hours after your first dose.,Do not stop fingolimod without consulting your doctor; stopping can cause severe return of MS symptoms.,Avoid grapefruit juice and Seville oranges.,Report any signs of infection, slow heart rate, or visual changes immediately.,Use effective contraception during treatment and for 2 months after stopping.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIDIL vs FINGOLIMOD, answered by our medical review team.
ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. FINGOLIMOD is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIDIL and FINGOLIMOD depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. The standard adult dose of FINGOLIMOD is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIDIL and FINGOLIMOD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. FINGOLIMOD is classified as Category C. FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular sept. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.